Efficacy of lipid-lowering therapy beyond statins to prevent cardiovascular events: a meta-analysis

被引：4
|
作者：
Dykun, Iryna [1 ]
Mincu, Raluca [1 ]
Hendricks, Stefanie [1 ]
Balcer, Bastian [1 ]
Totzeck, Matthias [1 ]
Rassaf, Tienush [1 ]
Mahabadi, Amir A. [1 ]
机构：
[1] Univ Duisburg Essen, Dept Cardiol & Vasc Med, Essen, Germany
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2020年 / 27卷 / 15期
关键词：
REDUCING LIPIDS; SAFETY; EZETIMIBE;
D O I：
10.1177/2047487319866992
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1675 / 1678
页数：4
相关论文
共 50 条
  • [41] Potential cardiovascular benefit of optimized lipid-lowering and antiplatelet therapy in patients with acute coronary syndrome - a simulation analysis
    Mark, Laszlo
    Gutman, Noemi
    Vitrai, Jozsef
    ORVOSI HETILAP, 2024, 165 (44) : 1746 - 1752
  • [42] Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis
    Hangying Ying
    Jiacheng Wang
    Zhida Shen
    Meihui Wang
    Binquan Zhou
    Cardiovascular Drugs and Therapy, 2021, 35 : 153 - 166
  • [43] Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
    Abdalwahab, Ahmed
    Al-Atta, Ayman
    Zaman, Azfar
    Alkhalil, Mohammad
    WORLD JOURNAL OF CARDIOLOGY, 2021, 13 (09): : 472 - 482
  • [44] Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials
    Poli, A.
    Corsini, A.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2010, 21 (05) : 372 - 373
  • [45] Bempedoic Acid can Reduce Cardiovascular Events in Combination with Statins or As Monotherapy: A Systematic Review and Meta-analysis
    Zhang, Ju
    Guan, Xiangfeng
    Zhang, Baixue
    Wang, Jia
    Jin, Xiaodong
    Zhao, Yunhe
    Li, Bo
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (06) : 695 - 708
  • [46] Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
    Sattar, Naveed
    Preiss, David
    Robinson, Jennifer G.
    Djedjos, C. Stephen
    Elliott, Mary
    Somaratne, Ransi
    Wasserman, Scott M.
    Raal, Frederick J.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05) : 403 - 410
  • [47] The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials
    Makris, Anastasios
    Barkas, Fotios
    Sfikakis, Petros P.
    Liberopoulos, Evangelos
    Agouridis, Aris P.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [48] STEP-RCV Project: ScienTific Expert Panel for patients at high and very high cardiovascular risk: how to optimize lipid-lowering therapy
    Colivicchi, Furio
    Arca, Marcello
    Di Fusco, Stefania Angela
    Pirillo, Angela
    Catapano, Alberico L.
    GIORNALE ITALIANO DI CARDIOLOGIA, 2024, 25 (05) : 318 - 326
  • [49] Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials
    Yang, Wenjia
    Cai, Xiaoling
    Lin, Chu
    Lv, Fang
    Zhu, Xingyun
    Han, Xueyao
    Ji, Linong
    MEDICINE, 2022, 101 (37) : E30563
  • [50] Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
    Xie, Sining
    Galimberti, Federica
    Olmastroni, Elena
    Luscher, Thomas F.
    Carugo, Stefano
    Catapano, Alberico L.
    Casula, Manuela
    CARDIOVASCULAR RESEARCH, 2024, 120 (04) : 333 - 344
12345